A retrospective analysis of taxane-based chemotherapy in small bowel adenocarcinoma
The Oncologist · 2026
DOI: 10.1093/oncolo/oyag104 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, 2026. Verfasst von Mir Lim und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, U…. Hauptthemen laut MEDLINE: Adenocarcinoma, Taxoids, Intestine, Small, Intestinal Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kavanagh Family Foundation and Kevin T. Doner Memorial Fund.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Small bowel adenocarcinoma (SBA) is molecularly distinct from colorectal and gastric cancers, yet treatment typically parallels colorectal cancer. We evaluated the activity of taxane-based therapy in the largest SBA cohort to date.
Methods
We retrospectively reviewed SBA patients treated with taxane-based chemotherapy at MD Anderson Cancer Center from 1994 to 2024. Eligible patients had pathologic confirmation, received >1 treatment cycle, and had tumor response evaluation. Survival analyses were analyzed using Kaplan–Meier and Cox proportional hazard models.
Results
Seventy patients were identified. Median age was 57, and 59% were male. Primary sites were duodenum (44%), jejunum (34%), and ileum (16%). Metastatic sites included peritoneum (39%) and liver (31%). Common mutations were TP53 (63%), KRAS (47%), SMAD4 (24%), and APC (15%). Taxanes were administered as single agents (29%) or in combination (71%), most often in second- (40%) or third-line (33%) settings. Overall response rate was 24%. Median time to progression (mTTP) was 3.1 months (95% CI: 2.0-4.2) and median overall survival (mOS) was 8.7 months (95% CI: 7.4-10.1). Efficacy did not differ by treatment line, regimen type, or tumor site, but was significantly associated with TP53 status; response rate was 20% in TP53-mutated vs 45% in wild-type (P = .009), with mTTP 2.5 vs 4.9 months (P = .009) and mOS 7.3 vs 10.6 months (P = .002). On multivariable analysis, TP53 mutation predicted worse outcomes.
Conclusion
Taxane-based therapy demonstrated activity in metastatic SBA, with 24% response and 3.1-month mTTP. TP53 mutation may be a negative predictive marker for taxane efficacy. These findings support prospective investigation in metastatic SBA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.
- Department of Medical Oncology, Mayo Comprehensive Cancer Center, Rochester, NY 55905, United States.
- Division of Hematology Oncology, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, United States.
- Department of Medical Oncology, Levine Cancer Institute, Atrium Health, Charlotte, NC 28204, United States.
- Department of Pathology, The University of Texas MD Anderson Cancer Center, Charlotte, NC 77030, United States.
ORCID-Profile: Mir Lim, Jane Thomas, Robert Wolff
Förderung
- Kavanagh Family Foundation and Kevin T. Doner Memorial Fund
Zitieren
APA
Lim, M., Grandhi, N., Shah, P., Raghav, K., Serpas, V., Morelli, M. P., Pedersen, K., Kalyan, A., Salem, M., Huey, R., Shen, J. P., Wang, H., Wang, H., Vinocha, A., Thomas, J., Wolff, R., & Overman, M. J. (2026). A retrospective analysis of taxane-based chemotherapy in small bowel adenocarcinoma. The Oncologist. https://doi.org/10.1093/oncolo/oyag104
Vancouver
Lim M, Grandhi N, Shah P, Raghav K, Serpas V, Morelli MP, et al. A retrospective analysis of taxane-based chemotherapy in small bowel adenocarcinoma. The Oncologist. 2026. doi:10.1093/oncolo/oyag104
BibTeX
@article{Lim2026,
author = {Lim, Mir and Grandhi, Nikhil and Shah, Preksha and Raghav, Kanwal and Serpas, Victoria and Morelli, Maria Pia and Pedersen, Katrina and Kalyan, Aparna and Salem, Mohamed and Huey, Ryan and Shen, John Paul and Wang, Huamin and Wang, Hua and Vinocha, Anjali and Thomas, Jane and Wolff, Robert and Overman, Michael J},
title = {A retrospective analysis of taxane-based chemotherapy in small bowel adenocarcinoma},
journal = {The Oncologist},
year = {2026},
doi = {10.1093/oncolo/oyag104}
}
EUVIMED